Keywords: TG Therapeutics, Rhizen Pharmaceuticals, TGR-1202, Hematologic cancers, Autoimmune diseases

TG Thera in up to $250 million deal with Rhizen

Article | 17 August 2012

Print This

US development stage company TG Therapeutics (GTX:OTC B) has entered into an exclusive global agreement with privately-held Swiss firm ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in